Journal of Animal Reproduction and Biotechnology (한국동물생명공학회지)

The Korean Society of Animal Reproduction and Biotechnology (한국동물생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Finasteride therapy in a dog with benign prostatic hyperplasia

  • Kim, Hyejin (Institute of Biomedical communications, Incheon Catholic University)
  • Received : 2022.08.23
  • Accepted : 2022.09.20
  • Published : 2022.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Benign prostatic hyperplasia (BPH) is frequently observed in intact middle-aged or older male dogs with symptoms ranging from asymptomatic to various symptoms such as urination, dyschezia, dysuria, tenesmus, and intermittent serosanguinous or clear serous exudate. A 4-year-old, intact male Welsh corgi with symptoms of intermittent hematuria and serosanguinous exudate at the urethral opening was diagnosed with BPH and intraprostatic hematocyst through ultrasonographic examination and cytology test. The dog was internationally adopted for reproductive purposes and needed to undergo BPH treatment while maintaining fertility. Thus, 2.5 mg finasteride was administered orally once a day for treatment option and therapeutic effects were observed, including loss of clinical symptoms and reduced prostate and intraparenchymal cyst size.

Keywords

Acknowledgement

The author is grateful to Haemaru Referral Animal Hospital, where the author had been in charge of a theriogenologist.

References

  1. Angrimani DSR, Brito MM, Rui BR, Nichi M, Vannucchi CI. 2020. Reproductive and endocrinological effects of Benign Prostatic Hyperplasia and finasteride therapy in dogs. Sci. Rep. 10:14834. https://doi.org/10.1038/s41598-020-71691-7
  2. Cohen SM, Werrmann JG, Rasmusson GH, Tanaka WK, Malatesta PF, Prahalada S, Jacobs JG, Harris G, Nett TM. 1995. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. Prostate 26:55-71. https://doi.org/10.1002/pros.2990260202
  3. Johnston SD, Root Kustritz MV, Olson PNS. 2001. Canine and Feline Theriogenology. Saunders, Philadelphia, pp. 337-341.
  4. Laroque PA, Prahalada S, Molon-Noblot S, Cohen SM, Soper K, Duprat P, Peter CP, van Zwieten MJ. 1995. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors. Prostate 27:121-128. https://doi.org/10.1002/pros.2990270302
  5. Lowseth LA, Gerlach RF, Gillett NA, Muggenburg BA. 1990. Age-related changes in the prostate and testes of the beagle dog. Vet. Pathol. 27:347-353. https://doi.org/10.1177/030098589002700507
  6. Nizanski W, Levy X, Ochota M, Pasikowska J. 2014. Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update. Reprod. Domest. Anim. 49 Suppl 2:8-15. https://doi.org/10.1111/rda.12297
  7. Peters DH and Sorkin EM. 1993. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs 46:177-208. https://doi.org/10.2165/00003495-199346010-00010
  8. Selman SH. 2011. The McNeal prostate: a review. Urology 78:1224-1228. https://doi.org/10.1016/j.urology.2011.07.1395
  9. Sirinarumitr K, Sirinarumitr T, Johnston SD, Sarkar DK, Kustritz MV. 2002. Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy. Am. J. Vet. Res. 63:495-498. https://doi.org/10.2460/ajvr.2002.63.495